Vertex Pharmaceuticals Management
Management criteria checks 2/4
Vertex Pharmaceuticals' CEO is Reshma Kewalramani, appointed in Apr 2020, has a tenure of 4.67 years. total yearly compensation is $20.59M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth $30.10M. The average tenure of the management team and the board of directors is 5.2 years and 4.8 years respectively.
Key information
Reshma Kewalramani
Chief executive officer
US$20.6m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.03% |
| Management average tenure | 5.2yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Dec 11Vertex Pharma: Why I Am Buying This Dip
Nov 25Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
Compensation vs Market: Reshma's total compensation ($USD20.59M) is above average for companies of similar size in the US market ($USD12.85M).
Compensation vs Earnings: Reshma's compensation has increased whilst the company is unprofitable.
CEO
Reshma Kewalramani (51 yo)
4.7yrs
Tenure
US$20,594,441
Compensation
Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 15.4yrs | US$6.60m | 0.0040% $ 4.1m | |
| CEO, President & Director | 4.7yrs | US$20.59m | 0.029% $ 30.1m | |
| Executive VP & CFO | 5.7yrs | US$7.37m | 0.017% $ 17.5m | |
| Executive VP & COO | 3.4yrs | US$9.00m | 0.019% $ 19.8m | |
| Executive VP & Chief Scientific Officer | 9.9yrs | US$6.54m | 0.010% $ 10.3m | |
| Senior VP & Chief Accounting Officer | 3.6yrs | no data | 0.0029% $ 3.0m | |
| SVP and Chief Information & Data Officer | 5.9yrs | no data | no data | |
| Senior Vice President of Investor Relations | 2.3yrs | no data | no data | |
| Executive VP & Chief Legal Officer | 2.3yrs | no data | 0.0065% $ 6.6m | |
| Senior VP & Chief Communications Officer | 5.9yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 7.3yrs | no data | no data | |
| Executive VP & Chief Patient and External Affairs Officer | 17.4yrs | US$6.20m | 0.023% $ 23.1m |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Management: VRTX's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 15.4yrs | US$6.60m | 0.0040% $ 4.1m | |
| CEO, President & Director | 4.8yrs | US$20.59m | 0.029% $ 30.1m | |
| Lead Independent Director | 26.9yrs | US$600.04k | 0.016% $ 15.9m | |
| Independent Director | 7.5yrs | US$537.63k | 0.0023% $ 2.3m | |
| Independent Director | 5.8yrs | US$559.79k | 0.0021% $ 2.1m | |
| Independent Director | 9.5yrs | US$550.31k | 0.0013% $ 1.4m | |
| Independent Director | 1.2yrs | US$449.08k | no data | |
| Independent Director | 4.5yrs | US$553.11k | 0.00064% $ 654.8k | |
| Independent Director | 2.6yrs | US$544.66k | 0.00060% $ 613.9k | |
| Independent Director | less than a year | US$407.65k | no data | |
| Independent Director | less than a year | no data | no data |
4.8yrs
Average Tenure
59yo
Average Age
Experienced Board: VRTX's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 77 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |